Specimen index
Peptide Database
8 peptides — filtered results
PT-141
ApprovedBremelanotide · Vyleesi
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist, FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through MC3R and MC4R receptors in the hypothalamus to initiate sexual arousal, making it effective for psychological as well as physiological sexual dysfunction. Research also explores applications in male erectile dysfunction.
Selank
ApprovedSelanc · TP-7
Selank is a synthetic heptapeptide analog of tuftsin developed by the Russian Institute of Molecular Genetics. Approved in Russia for anxiety and cognitive disorders, it exhibits anxiolytic effects comparable to benzodiazepines without sedation or dependence. Research shows it modulates GABA, serotonin, and dopamine systems, enhances BDNF expression, and improves memory consolidation and learning.
C₃₃H₅₇N₁₁O₉ · 751.87 Da
Semaglutide
ApprovedOzempic · Wegovy
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.
Semax
ApprovedMEHFPGP · Pro8-Gly9-Pro10-ACTH(4–10)
Semax is a synthetic heptapeptide analog of ACTH(4-7) developed in Russia, where it is approved for stroke, TBI, peptic ulcers, and cognitive enhancement. It upregulates BDNF and its receptor TrkB, promotes dopamine and serotonin turnover, and has demonstrated neuroprotective effects in ischemia models. Research highlights improvements in attention, memory, and recovery from neurological injury.
Sermorelin
ApprovedGHRH(1-29) · GRF 1-29 NH2
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and secrete growth hormone in a pulsatile, physiologic manner. FDA-approved for GH deficiency in children, it is extensively researched in adults for body composition, sleep quality, and age-related GH decline.
C₁₄₉H₂₄₆N₄₄O₄₂S · 3357.88 Da
Tesamorelin
ApprovedEgrifta · TH9507
Tesamorelin is a stabilized synthetic GHRH analog FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pulsatile GH secretion while preserving natural feedback regulation. Research demonstrates significant visceral adipose tissue reduction, improved lipid profiles, and cognitive benefits, making it a key study compound for metabolic dysfunction.
Thymosin Alpha-1
ApprovedThymalfasin · Tα1
Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide derived from thymosin fraction 5 of the thymus gland. Approved in over 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy, it enhances T-cell maturation, dendritic cell function, and NK cell activity. Research continues to expand into sepsis, COVID-19, autoimmune conditions, and vaccine response enhancement.
C₁₂₉H₂₁₅N₃₃O₅₅ · 3108.29 Da
Tirzepatide
ApprovedMounjaro · Zepbound
Tirzepatide is the first dual GIP/GLP-1 receptor agonist, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). By co-activating both incretin receptors, it achieves superior glycemic control and weight reduction compared to GLP-1 monotherapy — SURMOUNT trials showed up to 22.5% body weight reduction. It represents a new class of metabolic peptide therapeutics with broad cardiovascular and metabolic benefits.